Suzanne Elvidge

Biography for Suzanne Elvidge

Suzanne Elvidge has been involved in biopharma science and business publishing and journalism for over twenty years. She became the editor of FierceBiomarkers in November 2011, and has also written for FierceVaccines and FierceDrugDelivery. As a freelance writer she has written news and features for a range of online and print publications including European Life Science, the Journal of Life Sciences (now the Burrill Report), In Vivo, Life Science Leader, Nature Biotechnology, PR Week and Start-Up. She is also the editor of Genome Engineering, a blog that monitors the latest developments in genome engineering. She lives in the Peak District, in a very rural part of Derbyshire, U.K., with her second-hand bookseller husband and two second-hand cats. She can be reached at selvidge@fiercemarkets.com. Follow @suzannewriter on Twitter.

Articles by Suzanne Elvidge

Tumor necrosis factor supports cancer vaccine

Researchers from the University of Western Australia found that low doses of TNFα (tumor necrosis factor α) targeted to a pancreatic tumor enhanced the ability of immune cells (T cells) to get inside the tumor.

Making safer and better shots

Researchers at the Oregon National Primate Research Center have published a new method in Nature Medicine that could make vaccines even safer, and more effective as well.

Oral TB vax could cut treatment time

Phase II results of Immune Network's therapeutic tuberculosis vaccine were presented at the Drug Resistance and Persistence in Tuberculosis meeting in Uganda, part of the Keystone Symposia Global Health Series.

Taking the pain out of shots

A team of engineers at MIT has developed a jet delivery technology that shoots the vaccine (or therapeutic) through the skin and is less painful than a needle.

Wishing you a happy HIV Vaccine Awareness Day

I want to wish you a belated happy HIV Vaccine Awareness Day for 18 May from FierceVaccines and share with you part of a statement from Anthony S. Fauci, M.D.

HIV vaccine carries its own adjuvant into clinical trials

The trial will include 48 people at four sites in the U.S., 40 receiving the vaccine at increasing doses and 8 as controls, and will check the safety of the vaccine while looking out for an immune response.

DNA vaccine swats TB and HIV

TB is the leading cause of death among people with HIV infection, and being able to give people a shot that treats HIV and protects against TB would be a major breakthrough for this vulnerable group of people.

Vitamin D boosts TB shot as cancer therapy

The Bacillus Calmette-Guérin vaccine works in superficial bladder cancer, treating early stage disease and cutting recurrences. Vitamin D is linked with boosting the immune system, so researchers are looking at mice with bladder cancer to see what happens when you combine the two.

Vax-chemo combo offers some hope in pancreatic cancer

Pancreatic cancer is hard to treat, but adding a cancer vaccine to standard chemotherapy could boost survival.

Army uses ducks and DNA vax to make antivirals

The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and its collaborators have created a route to producing an antibody-based treatment using a DNA vaccine and duck eggs.